[144] PTC THERAPEUTICS, INC. SEC Filing

Rhea-AI Filing Summary

Form 144 filing for PTC Therapeutics (PTCT) reporting a proposed sale of 2,266 common shares held by the named person through a broker on 10/06/2025, with an aggregate market value of $147,453.25. The securities were acquired as an option granted on 01/05/2023 and the intended sale is to be settled for cash. The filer also disclosed multiple recent sales by the same person during the prior three months: 2,813 shares on 08/15/2025, 22,664 shares on 09/11/2025, 24,585 shares on 09/12/2025, and 22,655 shares on 10/03/2025, generating gross proceeds in the six-figure to low seven-figure range. The filing includes the broker name (Fidelity Brokerage Services LLC) and indicates trades on NASDAQ.

Positive

• Securities were acquired via an option grant (01/05/2023), indicating a standard equity compensation origin rather than an external purchase
• Broker disclosed as Fidelity Brokerage Services LLC, and trades are executed on NASDAQ, providing transparent execution routing

Negative

• Significant recent insider sales: 72,717 shares sold across four transactions in the past three months, indicating notable insider liquidity
• Aggregate market value of the current proposed sale is $147,453.25, and recent single-day proceeds exceeded $1.38M, which may increase selling pressure on float

Insights

Equity Compensation Analyst

Insider option exercise and ongoing open-market sales; size and timing matter.

The filer intends to sell 2,266 shares acquired via an option grant dated 01/05/2023, settled for cash through Fidelity on 10/06/2025. This is consistent with exercising and liquidating equity compensation rather than a corporate financing event.

Material context comes from four prior sales in the last three months totaling over 72,717 shares, producing multi‑hundred‑thousand to >$1.3M proceeds on some dates. That pace could affect perceived insider conviction and short‑term float; monitor the cumulative shares sold vs. total outstanding of 79,438,094 shares for dilution context.

Watch near term: confirm whether sales follow a prearranged 10b5-1 plan (no plan date is provided) and whether the seller continues similar-sized disposals over the next 30-90 days.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	2266	147453.25	79438094	10/06/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/06/2025	Option Granted - 01/05/2023	Issuer			2266	10/06/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mark Boulding 500 Warren Corporate Center Drive Warren NJ 07059	Common	08/15/2025	2813	136646.45
Mark Boulding 500 Warren Corporate Center Drive Warren NJ 07059	Common	09/11/2025	22664	1382537.63
Mark Boulding 500 Warren Corporate Center Drive Warren NJ 07059	Common	09/12/2025	24585	1508093.64
Mark Boulding 500 Warren Corporate Center Drive Warren NJ 07059	Common	10/03/2025	22655	1491105.66

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the PTCT Form 144 disclose about the planned sale?

It reports a proposed sale of 2,266 common shares on 10/06/2025 with an aggregate market value of $147,453.25 to be executed through Fidelity Brokerage Services LLC on NASDAQ.

How were the shares being sold acquired by the filer?

The shares were acquired via an option granted on 01/05/2023 and the current sale is to be paid in cash.

Has the filer sold other PTCT shares recently?

Yes. The filer sold 2,813 shares on 08/15/2025, 22,664 on 09/11/2025, 24,585 on 09/12/2025, and 22,655 on 10/03/2025.

Does the filing state whether a 10b5-1 trading plan was used?

No plan adoption date or explicit statement that a 10b5-1 trading plan is being relied upon is provided in the filing.

What is the company share count context provided?

The filing lists 79,438,094 shares outstanding, which provides context for the relative size of the disclosed sales.